Next Article in Journal
Vegetarian Diets, Ayurveda, and the Case for an Integrative Nutrition Science
Next Article in Special Issue
Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach
Previous Article in Journal
A Novel Procedure for the Management of Severe Hyphema after Glaucoma Filtering Surgery: Air–Blood Exchange under a Slit-Lamp Biomicroscopy
Previous Article in Special Issue
Validity of Clinical Assessment Using Clinical Symptoms and C-Reactive Protein for Therapeutic Response in Pyogenic Vertebral Osteomyelitis: Analysis Based on 18F-FDG-PET
Communication

The “Undetermined Significance” of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

1
Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
2
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, 1011 Lausanne, Switzerland
3
Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
4
Faculty of Biology and Medicine, University of Lausanne, 1011 Lausanne, Switzerland
5
Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland
6
Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: François Cornelis
Received: 2 August 2021 / Revised: 20 August 2021 / Accepted: 21 August 2021 / Published: 23 August 2021
(This article belongs to the Special Issue 2-[18F]-FDG PET/CT in Oncology: New Evidences and Future Perspectives)
Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent condition with the possible risk of progression to multiple myeloma (MM) or a lymphoproliferative neoplasm in a small percentage of patients. Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI) are imaging methods increasingly used in patients with MM. The aim of this communication is to underline that, taking into account current evidence-based data, compared to MM the role of 18F-FDG PET/CT or PET/MRI in MGUS is still undetermined and more studies should be performed before suggesting 18F-FDG PET/CT or PET/MRI for evaluation of MM progression in patients with MGUS. View Full-Text
Keywords: PET; FDG; MGUS; myeloma; monoclonal gammopathy; plasma cell; evidence-based; recommendation; imaging PET; FDG; MGUS; myeloma; monoclonal gammopathy; plasma cell; evidence-based; recommendation; imaging
MDPI and ACS Style

Treglia, G.; Bertagna, F.; Albano, D. The “Undetermined Significance” of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). Medicina 2021, 57, 856. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57080856

AMA Style

Treglia G, Bertagna F, Albano D. The “Undetermined Significance” of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). Medicina. 2021; 57(8):856. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57080856

Chicago/Turabian Style

Treglia, Giorgio, Francesco Bertagna, and Domenico Albano. 2021. "The “Undetermined Significance” of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)" Medicina 57, no. 8: 856. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57080856

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop